cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
C4 Therapeutics Inc
1 own
1 watching
Current Price
$0
$0.22
(2.78%)
logo-cccc
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
387.2M
52-Week High
52-Week High
26.8
52-Week Low
52-Week Low
4.84
Average Volume
Average Volume
0.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization387.2M
icon52-Week High26.8
icon52-Week Low4.84
iconAverage Volume0.3M
iconDividend Yield--
iconP/E Ratio--
What does the C4 Therapeutics Inc do?
We are a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. --- We were incorporated in October 2015 under the laws of the State of Delaware. Our principal executive offices are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472, and our telephone number is (617) 231-0700.We have one wholly owned subsidiary, C4T Securities Corporation, a Massachusetts corporation. Our website address is www.c4therapeutics.com.
Read More
How much money does C4 Therapeutics Inc make?
News & Events about C4 Therapeutics Inc.
Globe Newswire
3days ago
WATERTOWN, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today ...
Globe Newswire
24days ago
Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone Phase 1/2 Trial of CFT8634, a BRD9 BiDAC Degrader, Continues to Progress with Phase 1 ...
Ticker Report
2 months ago
Vickers Vantage Corp. I (NASDAQ:VCKA Get Rating) and C4 Therapeutics (NASDAQ:CCCC Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability...
Zolmax
8 months ago
C4 Therapeutics, Inc. (NASDAQ:CCCC Get Rating) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 3,900,000 shares, a decline of 23.7% from the April 30th total of 5,110,000 shares. Currently, 10.2% of the companys shares are short sold. ...
Globe Newswire
9 months ago
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of C4 Therapeutics, Inc. (C4 or the Company) (NASDAQ: CCCC). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation ...
Frequently Asked Questions
Frequently Asked Questions
What is C4 Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy C4 Therapeutics Inc shares?
plus_minus_icon
How can I buy C4 Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of C4 Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in C4 Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of C4 Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of C4 Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of C4 Therapeutics Inc?
plus_minus_icon
What percentage is C4 Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is C4 Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.22
(2.78%)
logo-cccc
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00